preclinical and clinical studies of clindamycin-2-phosphate developed as an infectable were conducted , and the following results were obtained : 1 ) clindamycin-2-phosphate administered by the intravenous drip in a dose of 600 mg over one hour showed a peak blood clindamycin level of 10.5 mcg/ml at the end of administration .
C0055881
clindamycin-2-phosphate
C0008947
clindamycin